The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.

Stifel raised the firm’s price target on Insmed (INSM) to $145 from $121 and keeps a Buy rating on the shares following FDA’s recent approval of ...

Truist raised the firm’s price target on Insmed (INSM) to $139 from $126 and keeps a Buy rating on the shares. The firm is positive on the stock and updating its model following approval of BRINSUPRI ...

Devarakonda covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Scholar Rock Holding, and Incyte. According to TipRanks, Devarakonda has an average return of -2.8% and a 37.04 ...